Fenofibrate/simvastatin, sold under the brand name Cholib, is a fixed-dose combination medication used to treat abnormal blood lipid levels when used in combination with a low-fat diet and exercise. It contains fenofibrate and simvastatin. It was approved for use in the European Union in August 2013.
Medical uses Fenofibrate/simvastatin is indicated as adjunctive therapy to diet and exercise in high cardiovascular risk adults with mixed dyslipidemia to reduce triglycerides and increase HDL C levels when LDL C levels are adequately controlled with the corresponding dose of simvastatin monotherapy.
Adverse effects
References
Further reading Filippatos TD, Elisaf MS (2015). "Safety considerations with fenofibrate/simvastatin combination". Expert Opin Drug Saf. 14 (9): 1481–93. doi:10.1517/14740338.2015.1056778. PMID 26134595. S2CID 207488283. Tarantino N, Santoro F, De Gennaro L, Correale M, Guastafierro F, Gaglione A, et al. (2017). "Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy". Vasc Health Risk Manag. 13: 29–41. doi:10.2147/VHRM.S95044. PMC 5317328. PMID 28243111.{{cite journal}}: CS1 maint: overridden setting (link)